ArticleJornal brasileiro de nefrologia
The Brazilian registry of kidney biopsies: results from the 2022 national prospective registry.
Article in Jornal brasileiro de nefrologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionKidney biopsy plays a central role in the etiological diagnosis and management of kidney diseases. The Brazilian Registry of Kidney Biopsies (BRKB) was established by the Brazilian Society of Nephrology to characterize biopsy-proven kidney diseases nationwide. The aim of this manuscript is to present the BRKB data for 2022.
methodsWe analyzed data from adult patients who underwent native kidney biopsy and were prospectively included in the BRKB between January and December 2022. Demographic, clinical, laboratory, and histopathological variables were evaluated.
resultsA total of 1,142 kidney biopsies from centers across all Brazilian regions were included. Female patients accounted for 54.8% of cases, and the mean age was 44.8 ± 16.4 years. The main indications for biopsy were kidney dysfunction (51.8%) and nephrotic syndrome (39.4%). Hypertension and diabetes mellitus were present in 47.8% and 15.1% of patients, respectively. At the time of biopsy, 67.1% had an estimated glomerular filtration rate < 60 mL/min/1.73 m2. Glomerular diseases were the most frequent histological diagnoses (72.5%), with lupus nephritis (23.1%), IgA nephropathy (15.0%), and focal segmental glomerulosclerosis (11.2%) being the most common.
conclusionThe 2022 BRKB data provide a contemporary overview of biopsy-proven kidney diseases in Brazil and highlight the predominance of glomerular disorders. Among diabetic patients undergoing biopsy, only half showed histological evidence of diabetic nephropathy, emphasizing the value of kidney biopsy in selected cases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.